Comparison of effects of dalteparin and enoxaparin on hemostatic parameters and von Willebrand factor in patients with unstable angina pectoris or non--ST- segment elevation acute myocardial infarction.

PubWeight™: 0.76‹?›

🔗 View Article (PMID 11867046)

Published in Am J Cardiol on March 01, 2002

Authors

Ronald Hödl1, Kurt Huber, Wilfried Kraxner, Mariam Nikfardjam, Martin Schumacher, Friedrich M Fruhwald, Gerlinde Zorn, Manfred Wonisch, Werner Klein

Author Affiliations

1: Division of Cardiology, Department of Medicine, Karl-Franzens University, Graz, Austria.

Articles by these authors

ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J (2012) 18.18

ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J (2011) 13.10

Guidelines on myocardial revascularization. Eur Heart J (2010) 8.85

Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J (2008) 8.20

Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet (2009) 6.92

Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation (2011) 6.48

Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med (2013) 6.01

Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med (2014) 5.25

Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med (2011) 4.81

Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med (2012) 4.49

Guidelines on myocardial revascularization. Eur J Cardiothorac Surg (2010) 3.47

Arterial puncture closing devices compared with standard manual compression after cardiac catheterization: systematic review and meta-analysis. JAMA (2004) 3.41

Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation (2013) 3.25

Clinical outcomes of health-care-associated infections and antimicrobial resistance in patients admitted to European intensive-care units: a cohort study. Lancet Infect Dis (2010) 3.23

Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med (2011) 3.20

Implementation of guidelines improves the standard of care: the Viennese registry on reperfusion strategies in ST-elevation myocardial infarction (Vienna STEMI registry). Circulation (2006) 3.08

Undue reliance on I(2) in assessing heterogeneity may mislead. BMC Med Res Methodol (2008) 3.06

Does carotid stent cell design matter? Stroke (2008) 3.02

N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). J Am Coll Cardiol (2013) 2.90

Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease. Br J Haematol (2002) 2.88

Twenty years experience with an ileal orthotopic low pressure bladder substitute--lessons to be learned. J Urol (2006) 2.82

Bivalirudin started during emergency transport for primary PCI. N Engl J Med (2013) 2.80

Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries. Eur Heart J (2009) 2.68

Nerve sparing open radical retropubic prostatectomy--does it have an impact on urinary continence? J Urol (2006) 2.65

The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. Circulation (2013) 2.64

Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. Circulation (2008) 2.59

Consistent estimation of the expected Brier score in general survival models with right-censored event times. Biom J (2006) 2.55

Consensus document on the radial approach in percutaneous cardiovascular interventions: position paper by the European Association of Percutaneous Cardiovascular Interventions and Working Groups on Acute Cardiac Care** and Thrombosis of the European Society of Cardiology. EuroIntervention (2013) 2.48

New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. J Am Coll Cardiol (2012) 2.41

Determinants and prognostic impact of heart failure complicating acute coronary syndromes: observations from the Global Registry of Acute Coronary Events (GRACE). Circulation (2004) 2.38

Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. Thromb Haemost (2014) 2.29

Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy. JAMA (2012) 2.22

Effect of home-based telemonitoring using mobile phone technology on the outcome of heart failure patients after an episode of acute decompensation: randomized controlled trial. J Med Internet Res (2009) 2.17

2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). Eur Heart J (2014) 2.10

Short versus prolonged bed rest after uncomplicated acute myocardial infarction: a systematic review and meta-analysis. J Clin Epidemiol (2003) 2.01

How to use high-sensitivity cardiac troponins in acute cardiac care. Eur Heart J (2012) 2.00

The performance of risk prediction models. Biom J (2008) 2.00

Risk factors for the development of nosocomial pneumonia and mortality on intensive care units: application of competing risks models. Crit Care (2008) 1.98

Effect of intravenous FX06 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction results of the F.I.R.E. (Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury) trial. J Am Coll Cardiol (2009) 1.98

Proportional subdistribution hazards modeling offers a summary analysis, even if misspecified. Stat Med (2010) 1.94

Management of grown up congenital heart disease. Eur Heart J (2003) 1.94

A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics (2008) 1.92

Simvastatin blunts endotoxin-induced tissue factor in vivo. Circulation (2005) 1.89

Recommendations for the use of cardiac troponin measurement in acute cardiac care. Eur Heart J (2010) 1.88

How many infections are caused by patient-to-patient transmission in intensive care units? Crit Care Med (2005) 1.87

Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J (2014) 1.81

Profibrinolytic, antithrombotic, and antiinflammatory effects of an insulin-sensitizing strategy in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Circulation (2011) 1.81

Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial. Lancet (2011) 1.80

Allowing for mandatory covariates in boosting estimation of sparse high-dimensional survival models. BMC Bioinformatics (2008) 1.78

Transvenous treatment of carotid cavernous and dural arteriovenous fistulae: results for 31 patients and review of the literature. Neurosurgery (2003) 1.76

Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients. Clin Cancer Res (2006) 1.75

Prospective population-based study of viral lower respiratory tract infections in children under 3 years of age (the PRI.DE study). Eur J Pediatr (2004) 1.72

Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial. Circulation (2009) 1.69

Modeling the effect of time-dependent exposure on intensive care unit mortality. Intensive Care Med (2009) 1.66

Risk score for peri-interventional complications of carotid artery stenting. Stroke (2006) 1.63

Simulating competing risks data in survival analysis. Stat Med (2009) 1.62

Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation (2009) 1.60

On pseudo-values for regression analysis in competing risks models. Lifetime Data Anal (2008) 1.60

Circadian incidence of non-inflammatory retinal artery occlusions. Graefes Arch Clin Exp Ophthalmol (2008) 1.59

2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). Eur J Anaesthesiol (2014) 1.59

Oncologic, functional, and complications outcomes of robot-assisted radical cystectomy with totally intracorporeal neobladder diversion. Eur Urol (2013) 1.58

Plasma concentrations of interleukin-6, organ failure, vasopressor support, and successful coronary revascularization in predicting 30-day mortality of patients with cardiogenic shock complicating acute myocardial infarction. Crit Care Med (2006) 1.58

Differential effect of ischaemic preconditioning on mobilisation and recruitment of haematopoietic and mesenchymal stem cells in porcine myocardial ischaemia-reperfusion. Thromb Haemost (2010) 1.58

Efron-type measures of prediction error for survival analysis. Biometrics (2007) 1.58

Implications of diabetes in patients with acute coronary syndromes. The Global Registry of Acute Coronary Events. Arch Intern Med (2004) 1.57

Chlamydia pneumoniae in carotid artery atherosclerosis: a comparison of its presence in atherosclerotic plaque, healthy vessels, and circulating leukocytes from the same individuals. Stroke (2002) 1.55

Valproate-induced encephalopathy: assessment with MR imaging and 1H MR spectroscopy. Epilepsia (2002) 1.55

The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial. J Am Coll Cardiol (2003) 1.54

Quality control after cochlear implant surgery by means of rotational tomography. Otol Neurotol (2005) 1.54

Impact of clopidogrel loading dose on clinical outcome in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Heart (2010) 1.53

Non-conventional markers of atherosclerosis before and after gastric banding surgery. Eur Heart J (2009) 1.53

Antiplatelet treatment for prevention of cerebrovascular events in patients with vascular diseases: a systematic review and meta-analysis. Stroke (2013) 1.53

[Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation]. G Ital Cardiol (Rome) (2009) 1.52

Incorporating pathway information into boosting estimation of high-dimensional risk prediction models. BMC Bioinformatics (2009) 1.52

Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis. BMJ (2012) 1.51

Can a commercial diagnostic ultrasound device accelerate thrombolysis? An in vitro skull model. Stroke (2004) 1.51

A multi-biomarker risk score improves prediction of long-term mortality in patients with advanced heart failure. Int J Cardiol (2012) 1.51

A mimic of sarcoidosis. Lancet (2007) 1.49

Early assessment of outcome in cardiogenic shock: relevance of plasma N-terminal pro-B-type natriuretic peptide and interleukin-6 levels. Crit Care Med (2009) 1.48

Use of abciximab prior to primary angioplasty in STEMI results in early recanalization of the infarct-related artery and improved myocardial tissue reperfusion - results of the Austrian multi-centre randomized ReoPro-BRIDGING Study. Eur Heart J (2004) 1.48

The role of European national journals in education. Heart (2009) 1.46

Use of the alkaline in vivo Comet assay for mechanistic genotoxicity investigations. Mutagenesis (2004) 1.44

The honey man--second degree heart block after honey intoxication. Int J Cardiol (2008) 1.43

Solitary spinal artery aneurysms as a rare source of spinal subarachnoid hemorrhage: potential etiology and treatment strategy. AJNR Am J Neuroradiol (2005) 1.43

Recommendations for the use of natriuretic peptides in acute cardiac care: a position statement from the Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care. Eur Heart J (2011) 1.42

The relationship between quality of research and citation frequency. BMC Med Res Methodol (2006) 1.40

[Neuropsychiatric involvement in systemic lupus erythematosus. Part 2: diagnostic and therapy]. Med Klin (Munich) (2003) 1.40

Intrathecal gadolinium-enhanced MR myelography showing multiple dural leakages in a patient with Marfan syndrome. AJR Am J Roentgenol (2005) 1.40

Atorvastatin reduces thrombin generation after percutaneous coronary intervention independent of soluble tissue factor. Thromb Res (2004) 1.39

The pre-hospital fibrinolysis experience in Europe and North America and implications for wider dissemination. JACC Cardiovasc Interv (2011) 1.38

A competing risks analysis of bloodstream infection after stem-cell transplantation using subdistribution hazards and cause-specific hazards. Stat Med (2007) 1.37

Different effects of exercise on plasma concentrations of nebivolol, bisoprolol and carvedilol. Cardiovasc Drugs Ther (2004) 1.37

Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. Thromb Haemost (2013) 1.36

Bleeding risk assessment and management in atrial fibrillation patients. Executive Summary of a Position Document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis. Thromb Haemost (2011) 1.35

Serial noninvasive in vivo positron emission tomographic tracking of percutaneously intramyocardially injected autologous porcine mesenchymal stem cells modified for transgene reporter gene expression. Circ Cardiovasc Imaging (2008) 1.34